

# 2021 HEALTHCARE AFFORDABILITY STATE POLICY SCORECARD

## Summary Report



## CONTENTS

INTRODUCTION .....	3
WHY FOCUS ON STATES? .....	4
DIGGING INTO THE DATA—WHAT DID WE LEARN? .....	4
CURB EXCESS PRICES: POLICY AND OUTCOME FINDINGS .....	6
A closer look at recommended policy actions .....	7
REDUCING LOW-VALUE CARE: POLICY AND OUTCOME FINDINGS .....	11
A closer look at recommended policy actions .....	12
EXTEND COVERAGE TO ALL RESIDENTS: POLICY AND OUTCOME FINDINGS .....	15
A closer look at recommended policy actions .....	15
MAKE OUT-OF-POCKET COSTS AFFORDABLE: POLICY AND OUTCOME FINDINGS...	20
A closer look at recommended policy actions .....	21
CONCLUSION .....	25
APPENDIX TABLE A .....	26

The 2021 Healthcare Affordability State Policy Scorecards and complementary materials were created with extensive input from Hub director Amanda Hunt; Hub policy analysts Alexandra Allen, Annaliese Johnson and Elise Lowry; and Hub communications lead Tad Lee. Special thanks to Lynn Quincy, Beth Beaudin-Seiler, Liz Jones, Sabah Bhatnagar, Sana Charania and our partners at Johns Hopkins University, who assisted with various stages of the work.

All materials produced as part of the Healthcare Affordability State Policy Scorecard project, including the methodology report and scorecards for individual states, are available on our website at: [www.HealthcareValueHub.org/Affordability-Scorecard](http://www.HealthcareValueHub.org/Affordability-Scorecard)

*Support for the Healthcare Affordability Scorecard project was provided by Arnold Ventures. The views expressed here do not necessarily reflect the views of the foundation.*

## Healthcare Affordability State Policy Scorecard

### INTRODUCTION

2020 was a landmark year that changed the health policy landscape for years to come. The COVID-19 pandemic highlighted many weaknesses in our healthcare system—including the high cost of coverage and care—that have too long been ignored. Poll after poll shows that healthcare affordability is a top issue that consumers on both sides of the political aisle want their policymakers to address.<sup>1</sup> Additionally, pre- and post-COVID survey data collected at both the state and national levels shows that people are delaying or forgoing coverage and care due to cost—or getting needed care but struggling to pay the resulting expense—and that these affordability burdens affect more than 50 percent of adults in some states.<sup>2</sup> Evidence of widespread problems goes far up the income ladder and affects people of every stripe, serving as a strong call for action that must be met with a comprehensive approach in order to improve healthcare affordability for all.

The Altarum Healthcare Value Hub's second iteration of the Healthcare Affordability State Policy Scorecard examines states' performance on a broad set of actions to make healthcare more affordable and allows users to: (1) do a quick and easy assessment of actions their state has already taken and (2) identify actions policymakers can take to further improve. Perhaps most importantly, the Scorecard shows the robust policy toolset that policymakers have available to address healthcare affordability by tackling the underlying drivers of affordability problems—most notably, excess prices—and ensuring that all residents can access coverage options with affordable premiums and cost-sharing provisions.

Unique features of the Scorecard include:

- ▲ **Comprehensiveness**—the Scorecard examines the full spectrum of healthcare affordability policy domains including:
  - Curbing excess healthcare prices;
  - Reducing the provision of low- and no-value care;
  - Extending affordable coverage to all residents; and
  - Ensuring that cost-sharing is affordable.
- ▲ **Balance**—states' scores take into account affordability-related outcomes, in addition to policy efforts, giving states credit for strong outcomes even if the policy environment lacks some key actions.
- ▲ A **unique dataset** that compiles state-level activity with respect to both policy and outcome measures across the four healthcare affordability domains.
- ▲ **Highly actionable information**—each Scorecard is accompanied by an easy-to-use state Policy Checklist communicating the state's progress toward passing healthcare affordability-related policies, as well as actions policymakers still must take.<sup>3</sup>
- ▲ This report provides **case study examples** of states across the country that have enacted the recommended policies and provides links to the evidence to support the recommended policies' use.

State Scorecards, as well as an Executive Summary and methodology report, can be found at: <https://www.healthcarevaluehub.org/affordability-scorecard>

## WHY FOCUS ON STATES?

States play an important role when it comes to making healthcare more affordable. They have the power to pass and implement policies to curb excess prices, expand coverage and limit cost-sharing for high-value care (among other interventions) and can exercise this authority to make healthcare more affordable for state residents, especially in the absence of slow-moving and/or politically gridlocked federal action.<sup>4</sup> Additionally, state policymakers are close to the local market conditions that influence healthcare affordability and are well-versed in their state's unique policy environment, including historic reasons for favoring or disfavoring certain policies.

Healthcare affordability is a complex issue with many moving parts. In some states, affordability problems may stem from a lack of affordable coverage, while other states may primarily grapple with high annual spending growth. As a result, the path to healthcare affordability is not a “one-size-fits-all” approach—the appropriate solutions vary depending on states' unique healthcare/health policy environments. This Scorecard recognizes this dynamic by producing a custom set of recommendations tailored to each state.

## DIGGING INTO THE DATA—WHAT DID WE LEARN?

In addition to highlighting health system weaknesses, the COVID-19 pandemic has also spurred policy change. Across the country, policymakers are taking a fresh look at many health and social policies, including coverage eligibility and cost-sharing requirements that ultimately impact affordability. While some of these policies have or will eventually expire, others may endure, creating an opportunity for progress in areas that previously failed to gain traction. There have been well over 100 state level, affordability-related policy developments since our previous Scorecard was released in January 2020.


## KEY FINDINGS

- ▲ No state earned a perfect score overall. The highest ranked state, **Massachusetts**, performed well on many policy and outcome measures, but earned only 65.3 out of 80 possible points—equating to a B-grade on healthcare affordability.
- ▲ While state performance varied significantly, the majority of states earned less than 45 out of 80 possible points, receiving an F grade on healthcare affordability.
- ▲ Our examination of policy measures to address excess prices assigned the top score to **Massachusetts**, with **Vermont** and **Delaware** tied at second place. However, **Maryland**—followed by **Rhode Island** and **Tennessee**—performed best in terms of *outcomes* (as measured by private payer inpatient prices as a percentage of Medicare rates).<sup>5</sup>
- ▲ Our ability to measure low-value care policies at the state level was limited due to lack of available data. For this category, **Massachusetts** and **Virginia** received the highest policy scores, but **Maine** and **New Hampshire** scored the best in terms of low-value care overuse.
- ▲ **California**, **Massachusetts** and **Washington** were the highest scoring states in terms of policy actions to extend affordable coverage to all state residents, while **Massachusetts**, the **District of Columbia** and **Rhode Island** scored the highest in terms of coverage outcomes (i.e., reducing the portion of the population that is uninsured). Still, more work needs to be done. Unlike our other domains, almost all states have taken one or more actions to improve access to coverage.

- ▲ **California** and **New York** scored the highest in terms of policies to make out-of-pocket costs affordable, followed by **Connecticut**. However, **Hawaii** residents (followed by people living in **Iowa**, **Rhode Island**, **Massachusetts**, **North Dakota** and **Vermont**) reported the lowest levels of forgoing needed care due to cost. This outcome measure—forgoing needed care due to cost—is quite narrow and does not account for other ways individuals ration care, such as cutting pills in half, skipping doses of medicine and delaying going to the doctor or having a procedure done. Thus, while eight percent of residents in the best performing state (**Hawaii**) and 19 percent of residents in the worst performing state (**Texas**) report forgoing needed care, the share of people reporting a broader array of affordability burdens is likely far higher.

## HEALTHCARE AFFORDABILITY STATE RANKS

The Healthcare Affordability State Policy Scorecard ranks 50 states and the District of Columbia on their adoption of evidence-based policy actions to improve healthcare affordability for residents. The Scorecard looks at both policies and outcomes across four areas that were implemented by Dec. 31, 2020.



Note: Source data was insufficient to create an estimate for Hawaii, New Jersey and South Carolina. For complete methodology, see Healthcare Affordability State Policy Scorecard Methodology, Healthcare Value Hub (November 2021).



## CURB EXCESS PRICES: POLICY AND OUTCOME FINDINGS

For well documented reasons, the healthcare prices that many Americans pay are unrelated to the cost of providing those services, and often exhibit unwarranted variation and excessive profit-taking.<sup>6</sup> This pricing problem is particularly acute for the uninsured and those with private health insurance (about 65% of the population). Even for people with generous, protective health coverage, high prices are embedded in the premiums they pay. A 2019 study found that roughly \$230.7 billion to \$240.5 billion of spending *each year* was associated with excess prices.<sup>7</sup>

A key reason for excess prices is the market power of hospitals and drug and device manufacturers.

Being the only provider in an area, having all hospitals in an area owned by the same system and lack of generic drug competition are all market conditions that allow prices to rise. A 2019 report found that most Americans live in areas with concentrated healthcare markets and that consolidation has been increasing.<sup>8</sup> Due to the profound impact of prices on affordability and the role of market concentration, policymaker action in this area is vital.

This section of the Scorecard examined the following policy approaches:

- ▲ All-payer or multi-payer claims database (APCD);
- ▲ All-payer health spending benchmarks;
- ▲ A permanently convened health spending oversight entity; and
- ▲ Free, public-facing healthcare price transparency that reflects negotiated rates and displays prices that are treatment- and provider-specific.


Outcome scores for this category compare each state's inpatient private payer prices versus Medicare rates—a measure known as the Private-to-Medicare Ratio (PMR)—for a basket of the top 25 most frequently provided inpatient services. Data used to calculate the scores was not available for **Hawaii** or **South Carolina**.

Curbing Excess Prices was the area of greatest state inaction, with 18 states not taking a single one of the recommended actions (see Figure 1). Our examination of policy measures to address the excess prices assigned the top score to **Massachusetts**, followed by **Delaware** and **Vermont**. **Maryland**, followed by **Rhode Island**, received the highest score in terms of outcomes (earning the lowest ratio of private payer inpatient prices compared to Medicare's allowed amounts for the top 25 most frequent inpatient services).


While the appropriateness of Medicare prices as a benchmark is debated, the prices are developed on a cost-basis and are adjusted based on a variety of factors (such as geographic region and hospital type), indicating that they are less affected by local market conditions that may give rise to excessive private payer prices. According to a Johns Hopkins University analysis commissioned by Altarum, average state inpatient private payer prices were 192% of Medicare prices in 2018.<sup>9</sup> Prices varied substantially by state—**New York** and **Alaska** had the highest inpatient private prices at 241% and 240% of Medicare prices, respectively, followed by **Indiana** (233%) and **West Virginia** (228%). **Maryland** and **Rhode Island** had the lowest inpatient private payer prices at 132% and 137% of Medicare prices, respectively, followed by **Tennessee** (146%) and **Louisiana** (150%). Maryland's low prices may be partly explained by its global budget model.<sup>10</sup>

FIGURE 1: STATE SCORE COMPARISON: CURB EXCESS PRICES IN THE SYSTEM

### Policy Scores



### Outcome Scores



Note: SC and HI are not included in this chart because data on private sector prices relative to Medicare prices were not available for these states.

Appendix A lists the Curbing Excess Prices policy scores for all states, along with the state rank for this Scorecard component.

## A CLOSER LOOK AT THE RECOMMENDED POLICY ACTIONS:

**All-payer or multi-payer claims databases:** APCDs are large-scale databases created by states that contain diverse types of healthcare data, including claims data from private insurance companies, state employee health benefit programs and, in some cases, Medicare and Medicaid.<sup>11</sup> These databases are critical tools for addressing excess prices. APCDs (or their near cousin, multi-payer claims datasets) can provide useful information on payment, utilization and disease patterns, which can be used by a wide range of stakeholders to aid in health system transformation efforts.

This was the area of greatest state action on within the Excess Prices category, with 31 states having an active APCD or an APCD in process.<sup>12</sup> It is important to recognize, however, that the quality of APCDs varies substantially—some APCDs contain claims data that represents only a small portion of the state’s population, while others (like New York’s) provide limited and/or outdated publicly available information.

**Oregon** published a report summarizing 54 use cases for its APCD (the Oregon All-Payer All-Claims database, or APAC), including: healthcare spending and cost trends; healthcare delivery system performance; healthcare utilization; population health; disease prevention; and insurance coverage.<sup>13</sup>

**Georgia** passed legislation in 2020 to lay the groundwork for the creation of an APCD by Jan. 1, 2023.<sup>14</sup> The law established an APCD advisory council, funding, design criteria, operational guidelines and noncompliance penalties.<sup>15</sup> However, the creation of the APCD is subject to appropriations, and was not funded in the FY 2021 budget.<sup>16</sup>

**All-payer spending targets or benchmarks:** As healthcare spending continues to increase faster than wages and the rest of the economy, establishing overall spending targets are an important tool for reigning in spending growth. While data from **Massachusetts** shows us that even voluntary targets are helpful, mandatory targets may be even more impactful. Quality benchmarks, such as those being developed in **Connecticut** and **Delaware**, are also important to ensure that efforts to reduce healthcare cost growth does not negatively impact health outcomes. Another novel idea in **Massachusetts** is setting benchmarks to limit the growth in out-of-pocket health spending.

Only five states had implemented this strategy as of Dec. 31, 2020: **Delaware**, **Maryland**, **Massachusetts**, **Rhode Island** and **Vermont**. Implementation of spending benchmarks in **Oregon** and **Connecticut** began in 2021.<sup>17</sup>

**Massachusetts** was the first state to create an annual cost growth benchmark to monitor total per capita healthcare spending. If the annual growth of total healthcare expenditures across all payers (public and private) exceeds the benchmark, the state's Health Policy Commission can require healthcare entities to implement Performance Improvement Plans and submit to strict monitoring. The Commission's 2021 Cost Trends Report found that total healthcare expenditures per capita grew 4.3 % in 2018-2019 and 3.6% in 2017-2018—above the benchmark rate of 3.1%. However, Massachusetts' spending growth was below the national average of 4.7% in 2019.<sup>18</sup>

In 2018, **Delaware** became the first state to both set a healthcare spending growth target *and* a suite of associated quality benchmarks.<sup>19</sup> Quality measures include: emergency department use; opioid overdose deaths and risk factors; and a suite of cardiovascular health measures.

Legislation passed in **Connecticut** directs the Office of Health Strategy (OHS) to develop annual healthcare cost benchmarks for calendar years 2021-2025. The OHS must also set targets for increased primary care spending as a percentage of total healthcare spending, to reach 10% by 2025, and develop quality benchmarks across all public and private payers beginning in 2022.<sup>20</sup>



**A permanently convened, health spending oversight entity:** All states regulate some parts of their healthcare systems, but many lack a comprehensive, inter-agency, multi-payer plan to address this enormous segment of their economies. In order to systematically and comprehensively address the healthcare affordability burdens of state residents (and inform health system transformation efforts more generally), states need an entity empowered to look across various types of health and social spending and to identify opportunities for improvement in terms of value for each dollar spent, quality short-comings and affordability problems for residents.

State oversight entities can take a variety of forms (see Table 1), but all that received credit on the Scorecard monitor healthcare spending in a comprehensive and systematic way.<sup>21</sup> Only seven states have implemented this strategy in a way that targets *all spending*: **Colorado, Connecticut, Delaware, Massachusetts, Oregon, Vermont and Washington**. Seven other states (**Maine, Maryland, New Hampshire, New York, Ohio, Pennsylvania and Rhode Island**) have implemented this strategy in ways that target narrower forms of spending, such as hospital or drug spending.

This strategy typically goes hand-in-hand with establishing health spending targets. **Colorado and Washington** were the only states to have an oversight entity targeting all spending, but no accompanying spending targets (**Connecticut and Oregon's** are awaiting implementation).

**Table 1**  
**Potential Areas of Responsibility of Healthcare Oversight Entities**

Category	Description
<b>Monitor Spending</b>	Many oversight agencies monitor spending in all or some of the major healthcare sectors (for example, hospital spending). They may also seek to identify the underlying cost-drivers, such as unnecessary services, lifestyle factors and rising prices. Oversight authorities' abilities are greatly influenced by whether the state has an all-payer claims database.
<b>Monitor Quality of Care/Disparities</b>	Oversight authorities may also be responsible for monitoring quality of care received in hospitals and other settings, as well as assessing disparities in health outcomes between populations.
<b>Recommendations</b>	Most, if not all, oversight authorities examined here have the power to make policy recommendations and present their findings about costs and quality in an annual report to their state legislature to increase transparency.
<b>Enforcement</b>	Some oversight agencies go beyond data and recommendations, with power to subpoena, convene stakeholders or enforce global budgets.
<b>Health Insurance</b>	Some oversight authorities incorporate a dimension of health insurance review into their work. These duties range from monitoring consumer access to insurance rates, health insurance rate review and the impact of mandated benefits on insurance plans.
<b>Pilots/Innovations</b>	Some oversight authorities are responsible for pilots and innovations designed to improve healthcare value, including overseeing the State Innovation Model grants provided by CMS.
<b>Aggregate Purchasing Power</b>	States can aggregate the health spending programs they administer in support of a high-performing health system. Oversight entities can potentially oversee the coordination effort that would be needed.

**Maryland's** Health Services Cost Review Commission monitors the efficiency and effectiveness of hospitals using financial data (revenue, expenditures and utilization) to inform the Commission's recommendations on global hospital spending targets, uncompensated care and community benefits.<sup>22</sup>

**Colorado's** Office of Saving People Money on Health Care works to reduce patient costs for hospital stays and expenses, improve price transparency, lower the price of prescription drugs and make health insurance more affordable.<sup>23</sup>

**Vermont's** Green Mountain Care Board (GMCB) has one of the most extensive portfolios of all the oversight entities we reviewed. The GMCB is empowered to: monitor spending and quality of care across sectors; operate the state's all-payer claims database; review health insurance rates and identify drivers of rate increases; oversee pilots and innovations; align activity across payers and make legislative recommendations.<sup>24</sup>

**Free, public-facing healthcare price transparency:** It is well established that prices for the same healthcare service can differ significantly across providers—even within the same geographic area.<sup>25</sup> Yet, it is almost impossible for consumers and policymakers to get reliable information about this pricing landscape. While “shopping” by patients is unlikely to drive down excess prices,<sup>26</sup> transparent pricing data can be used by researchers, payers, regulators and legislators to identify outliers and embrace targeted solutions like reference pricing, strategic network construction, rate setting and more (though success will depend on the level of provider competition in the market). For maximum impact, healthcare price transparency tools should reflect negotiated rates and display prices that are treatment- and provider-specific. Ideally, price transparency would be accompanied by consumer-friendly quality information and the website interface will have been thoroughly tested for consumer friendliness and usability; however, states were not scored on these dimensions.

Given that increasing price transparency is a broadly acceptable policy approach, we were surprised how few states scored well in this area. Just nine states received credit for this policy action: **Colorado, Florida, Maine, Maryland, Massachusetts, New Hampshire, Oregon, Utah and Washington.**

**Maine's** award winning CompareMaine.org is a user-friendly healthcare transparency website and is one of the only in the nation to present quality ratings alongside cost information. Consumers can compare the costs and quality of more than 220 procedures at more than 280 facilities in the state.<sup>27</sup>

**Maryland's** “Wear the Cost” price transparency website has data for just 13 procedures, but the site uniquely shows the portion of total cost that is associated with potentially avoidable complications.<sup>28</sup>

**Utah's** Office of the State Auditor published the “Utah Health Cost Compare” tool in March 2020 to give consumers the median amounts paid by both insurance carriers and patients using claims data from insurance companies to the state's APCD.<sup>29</sup> The tool is a result of a 2019 state law that requires the State Auditor to create and maintain a healthcare price transparency tool that is accessible by the public.<sup>30</sup>



## REDUCE LOW VALUE CARE: POLICY AND OUTCOME FINDINGS

Building on groundbreaking work conducted by the Institute of Medicine and Berwick and Hackbarth, a 2019 study found that approximately one-quarter of healthcare spending is wasted.<sup>31</sup> In other words, roughly 25 percent of healthcare spending does not result in better health. Researchers estimated that one category of healthcare waste—overtreatment/low-value care—drives \$75.7 billion to \$101.2 billion in health expenditures each year. The estimated annual savings from the implementation of measures to eliminate overtreatment/low-value care ranges from \$12.8 billion to \$28.6 billion. Failure to curtail this “waste” raises premiums and causes patients to endure unnecessary cost-sharing for services, inconvenience and, occasionally, medical harm.

Policies to reduce the provision of low-value care were difficult to assess at the state level. While the data is clear that significant spending is associated with low- and no-value care, evidence is still being developed with respect to the state policy actions that can reduce the provision of low- and no-value services.<sup>32</sup>

This section of the Scorecard examined the following policy approaches:

- ▲ Whether the state requires medical error reporting for two types of hospital-acquired infections—central line-associated bloodstream infections (CLABSI) and catheter-associated urinary tract infections (CAUTI)—and whether the reports are validated;
- ▲ Whether hospitals have adopted the CDC’s ‘Core Elements’ of antibiotic stewardship; and
- ▲ Whether the state measures the provision of low-value care in claims data and/or electronic health records (EHRs).


The previous 2020 iteration of the scorecard scored states on whether they followed Medicare’s lead in refusing to pay for services related to “never events”—serious reportable events, as identified by the National Quality Forum, that should never occur in a healthcare setting. However, this measure was removed from the current scorecard based on findings that, since Medicare issued that rule, all state Medicaid programs and many private insurance plans and hospitals have independently issued their own rules disallowing payment for never events, reducing the need to encourage state governments to implement further protections. However, it is worth noting that **Maine, New Jersey, Connecticut and Pennsylvania** passed laws explicitly prohibiting hospitals from billing patients for never events.

Measuring outcomes with respect to low-value care was also challenging because the receipt of unnecessary care, and the potential financial and health consequences, are rarely measured at the state-level. Outcome scores for this category drew from a custom analysis estimating each state’s overuse of 17 low-value care “indicator procedures” compared to the national average, produced by Johns Hopkins University (see accompanying Methodology Report for additional detail).

Only one state (**North Dakota**) had a true zero for this policy area, but four other states (**Hawaii, Kansas, Montana and Wyoming**) took actions so minimal that their policy scores rounded to zero. **Massachusetts** and **Virginia** received the highest policy scores, but **Maine** (followed by **Vermont, South Dakota and New Hampshire**) scored best in terms of outcomes, with substantially less overuse of low-value care than the national average (see Figure 2). **Rhode Island** had the greatest overuse of low-value care compared to the national average, followed by **Alabama, Pennsylvania and Nevada**.

FIGURE 2: STATE SCORE COMPARISON: REDUCE LOW-VALUE CARE

### Policy Scores



### Outcome Scores



Appendix A lists the Low-Value Care policy scores for all states, along with the state rank for this Scorecard component.

## A CLOSER LOOK AT THE RECOMMENDED POLICY ACTIONS:

**Validated reporting for medical errors.** Medical harm is a particularly egregious form of healthcare waste and there is little debate about the need to increase efforts to reduce it.<sup>33</sup> Medical harm can take many forms, including:

- ▲ Serious Reportable Events—more commonly called “never events;”
- ▲ Healthcare-acquired conditions;
- ▲ Healthcare-acquired infections;
- ▲ Medication errors; and
- ▲ Diagnostic errors.

There are no comprehensive assessments of the total cost that medical harm adds to our nation's healthcare bill.<sup>34</sup> Most studies are limited to the examination of a particular type of event, a particular population or a particular healthcare setting. Nonetheless, a compilation of available studies found that around 1 in 20 (6% of) patients are affected by preventable harm in medical care, which leads to disability or death around 12% of the time. Moreover, we know that the resources devoted to prevention—by hospitals, other healthcare providers and governmental agencies at the state and federal levels—are dwarfed by the resources spent to treat the consequences of this mostly preventable problem.<sup>35</sup> Beyond finances, the human cost is staggering.<sup>36</sup>

Strategies to reduce patient harm are fairly well understood but unevenly implemented. In part, this stems from a lack of public reporting. Tracking medical harm at the state level is an important component of comprehensive approach to improving patient safety.<sup>37</sup> There is broad agreement that the goal of reporting is not to “shame and blame” but to work across stakeholders to identify patterns and craft data-driven interventions that prevent future harm. Errors leading to preventable harm are almost always multifactorial.<sup>38</sup>

States that require reporting typically require reporting for just a few types of harm, such as selected healthcare-acquired conditions and/or healthcare-acquired infections. In this Scorecard, we used a national database that showed whether states required hospitals to report two common types of healthcare acquired infections: central line-associated bloodstream infections and catheter-associated urinary tract infections. In 2019, 26 states plus DC required hospitals to report at least one of these infections.<sup>39</sup> We also looked at whether reports were validated, as studies have identified serious problems with under-reporting of medical harm.<sup>40</sup> In 2019, 22 states plus DC validated reporting for at least one of these infections.<sup>41</sup>

**Antibiotic stewardship in acute care hospitals:** According to a national analysis, at least 30 percent of antibiotics prescribed in the outpatient setting are unnecessary, contributing to unnecessary spending and the rise of antibiotic resistant bacteria.<sup>42</sup> Most of these unnecessary antibiotics are prescribed for respiratory conditions caused by viruses—including common colds, viral sore throats, bronchitis and sinus and ear infections—which do not respond to antibiotics. State health agencies' roles in addressing this problem include coordinating and facilitating prevention activities, monitoring antibiotic resistance across the state, leveraging existing partnerships and resources, and developing policies to improve antimicrobial prescribing and use (a.k.a. antibiotic stewardship).<sup>43</sup>

As a means of assessing progress, this Scorecard scores states based on the percentage of the state's acute care hospitals that have adopted the CDC's 'Core Elements' for hospital antibiotic stewardship.<sup>44</sup> Proven benefits include protecting patients from unintended consequences, improving the treatment of infections and helping combat antibiotic resistance. State scores reflect their relative progress (vis-à-vis other states) towards 100 percent of acute care hospitals adopting the CDC's standards.<sup>45</sup>

Many states perform well on hospital antibiotic stewardship, with 24 states plus the District of Columbia reporting at least a 90% Core Elements adoption rate among the state's acute care hospitals. One hundred percent of hospitals in **Delaware, D.C. and Rhode Island** have adopted the CDC's Core Elements, while six states (**Hawaii, Kansas, Montana, North Dakota, South Dakota and Wyoming**) have a 75%-or-less adoption rate.

**Measuring low-value care in claims data and/or electronic health records:** For the most part, states (and even individual providers) are typically in the dark with respect to how often healthcare services depart from recommended clinical guidelines. More than 500 services have been identified as low- or no-value, according to the Choosing Wisely campaign.<sup>46</sup>

The first national study to examine spending on a subset of low-value health services among adults with commercial health insurance found considerable potential for cost savings. Studying insurance claims from more than 1.46 million adults, researchers found that spending on just 28 low-value medical services totaled \$32.8 million during 2013.<sup>47</sup>

While purchasers and providers play key roles in reducing the provision of low- and no-value care,<sup>48</sup> there are steps that states can take to facilitate coordinated, multi-stakeholder action, including: prioritizing the reduction of low-value care; building a culture of trust, innovation and improvement; establishing a shared language and purpose; and committing resources to measurement.<sup>49</sup> A critical first step is to measure the extent of low- and no-value care in claims data. While not all forms of low-value care can be successfully measured using claims data,<sup>50</sup> researchers have found that the use of different types of low-value services generally correlate with each other, suggesting that the provision of low-value services may be driven by common factors.<sup>51</sup> This Scorecard finds that only eight states had taken this step as of Dec. 31, 2020: **Colorado, Maine, Massachusetts, Minnesota, Oregon, Rhode Island, Virginia and Washington.**

The nonprofit **Virginia Center for Health Innovation (VCHI)** analyzed claims data and found that providers in the state ordered 5.4 million services that were considered low-value, resulting in over \$586 million, or \$9.09 per beneficiary per month, in wasteful spending in 2015.<sup>52</sup> Subsequently, the VCHI received a \$2.2 million grant from Arnold Ventures to create a statewide pilot aimed at reducing the provision of low-value care. The pilot will create a large-scale health system learning community and an employer task force on low-value healthcare. A latter part of the project will develop a set of consumer-driven measures.<sup>53</sup>

In March 2020, **Colorado's Center for Improving Value in Health Care (CIVHC)** released a report analyzing spending on 48 low-value services using claims data from 2015 through 2017 for 4.1 million Coloradans. Importantly, the report highlights the specific measures that account for the majority of spending on low-value care and provides breakouts by insurance payer and geographic region. Moving forward, CIVHC plans to generate and share provider-specific data to encourage improvement at the local level.<sup>54</sup>





## EXTENDING COVERAGE TO ALL RESIDENTS: POLICY AND OUTCOME FINDINGS

Without healthcare coverage, affording healthcare is almost impossible for the vast majority of American families. Roughly 8.6 percent of U.S. residents (28 million people) were uninsured in 2020, although this rate varies widely across states and by sub-population within states.<sup>55</sup> Health insurance makes a difference in whether and when people receive necessary medical care, where they get their care and, ultimately, how healthy they are. Uninsured people are far more likely than those with insurance to postpone needed healthcare or forgo it altogether.<sup>56</sup>

State policy decisions have a profound impact on enrollment into coverage. While outreach strategies, enrollment assistance, website design and other factors influence enrollment, this Scorecard domain focuses on policies that reduce the cost of coverage, as cost is the most frequently cited reason for being uninsured.<sup>57</sup> This section of the Scorecard examined the following policy approaches:

- ▲ Medicaid expansion implemented by Dec. 31, 2020;
- ▲ Supplemental premium subsidies, reinsurance, Medicaid Buy-In, Basic Health Plan or other options for families that earn too much to qualify for Medicaid;
- ▲ Coverage options for recent or undocumented immigrants; and
- ▲ Strong health insurance premium rate review for fully insured, private market coverage options.

States' *outcome* scores for this category reflect the percent of the state's population that was uninsured in 2019. States received higher scores for lower rates of uninsurance.

As Figure 3 shows, almost all states have taken one or more actions to improve access to coverage. No states scored zero points in this policy area; however, two states (**Oklahoma** and **Wyoming**) earned less than one point (out of 10) due to an overall lack of action to expand coverage or make it more affordable. **California**, **Massachusetts** and **Washington** scored highest in terms of *policy actions* to extend affordable coverage to all state residents while **Massachusetts**, the **District of Columbia** and **Rhode Island** scored highest in terms of coverage outcomes (i.e., reducing the portion of the population that is uninsured).


### A CLOSER LOOK AT THE RECOMMENDED POLICY ACTIONS:

**Expand Medicaid to 138% of the Federal Poverty Level:** Some of the most profound disparities that exist across states affect residents with incomes below 138% of the federal poverty level (FPL).<sup>58</sup> Nationally, more than two million low-income, uninsured adults fall into the “coverage gap” that results from state decisions not to expand Medicaid.<sup>59</sup> In these states, residents with household incomes above current Medicaid eligibility but below the lower limit for Marketplace premium tax credits face a dearth of coverage options. Strong evidence suggests that expanding Medicaid to all residents improves health outcomes, financial security and contributes to economic prosperity in a state.<sup>60</sup>


Research conducted for the Scorecard shows that **Wisconsin** has made Medicaid accessible to residents up to 100% of FPL (roughly \$12,880 per year for individuals and \$26,500 per year for a family of 4) and 37 states

FIGURE 3: STATE SCORE COMPARISON: EXTEND COVERAGE TO ALL RESIDENTS

### Policy Scores



### Outcome Scores



Appendix A lists the Extending Coverage to All Residents policy scores for all states, along with the state rank for this Scorecard component.

have made Medicaid available to residents at higher incomes. The **District of Columbia** is a national leader in this area, extending Medicaid eligibility for single adults up to 215% of FPL (221% of FPL for parents). The remaining states have residents that fall into the so-called “coverage gap,” although several of these states have made significant strides towards expand eligibility (such as **Missouri**, **Oklahoma** and **South Dakota**).

**Coverage options for residents with incomes above 138% of FPL:** Many who are uninsured (as well as those who struggle to afford insurance premiums) have incomes above 138% of FPL, or \$12,880 per year for an individual and \$26,500 for a family of four.<sup>61</sup> While not as common as Medicaid expansion, states are using a variety of approaches to provide residents with incomes above Medicaid thresholds affordable coverage options. All told, 17 states have taken one or more of the following policy actions: provide supplemental premium subsidies and/or establish a reinsurance program, Medicaid Buy-In, Basic Health Plan or Public Option.



**Wisconsin** is the only state that provides Medicaid to people with household incomes up to 100% of FPL. However, research examining the population with incomes between 100-138% of FPL found that Medicaid expansion produces lower premiums and out-of-pocket costs than subsidized Marketplace coverage.<sup>62,63</sup>

**Missouri** voters approved a ballot measure to expand Medicaid in 2020. Coverage expansion was set to begin in July 2021 but was delayed due to a lawsuit that reached the Supreme Court. The Court ruled in favor of the expansion in August 2021.<sup>64</sup>

**Oklahoma** voters approved a Medicaid expansion initiative in 2020 and expansion took effect in July of 2021.<sup>65</sup>

In November 2020, **South Dakota's** Secretary of State approved two Medicaid expansion ballot initiative petitions for circulation. One is an initiated constitutional amendment (which requires 33,921 signatures to get on the 2022 ballot) and the other is an initiated state statute (which requires 16,961 signatures). Advocates have until November 2021 to gather the signatures.<sup>66</sup>

The American Rescue Plan (ARP), passed in 2021, temporarily increased the availability and amount of federal premium assistance for consumers purchasing coverage through the Marketplaces. If made permanent, this assistance may reduce the need for reinsurance programs by sharply reducing the numbers of state residents eligible to participate. Those who would remain eligible under this scenario include high-income earners and those who are ineligible for subsidies due to reasons outside of income, such as recent immigration status (i.e. having legal permanent residency for less than five years) or the family glitch (whereby one member of the family has an offer of “affordable” employer coverage). As of this publication, the enhanced ARP premium assistance has not been made permanent; however, states that have implemented or are considering implementing reinsurance programs should monitor the situation.<sup>67</sup>

**Coverage for recent and undocumented immigrants:** According to Kaiser Family Foundation, an estimated 21.3 million noncitizens resided in the U.S. in 2019, constituting roughly 7 percent of the total population.<sup>68</sup> Noncitizens include lawfully present immigrants, as well as those without documented status. Noncitizens are significantly more likely than citizens to be uninsured. Among the nonelderly population, 25 percent of lawfully present immigrants and 46 percent of undocumented immigrants were uninsured in 2019, compared to 9 percent of citizens.<sup>69</sup>

In general, lawfully present immigrants must have a “qualified” immigration status to be eligible for Medicaid or CHIP and many must wait five years after obtaining qualified status before they may enroll. Although these families include workers, they are unlikely to work in industries that offer health coverage to employees.<sup>70</sup> Barriers to coverage cause significant hardship for these families and harm public health.

State policy options to cover recent immigrants include:

- ▲ Eliminating the five-year wait and extending Medicaid and CHIP coverage to lawfully present immigrant children and pregnant women without qualified status. In 2020, 25 states provided this option to legally

Reinsurance was the most common approach to reduce the cost of non-group premiums, increasing from 6 states in 2019 to 12 states in 2020. For example, **Delaware** received Federal approval to create a reinsurance program in 2019, which it implemented in 2020. Delaware residents earning above 400% of FPL will save up to 20% on their health insurance premiums in the individual market.<sup>71</sup>

Three states (**California**, **Massachusetts** and **Vermont**) augment Marketplace tax credit subsidies with state-provided subsidies to further lower the cost of coverage. California temporarily extended premium subsidies to individuals earning 200-600% FPL for 2020 through 2022 to increase the affordability of and expand access to coverage. Massachusetts, on the other hand, offers subsidies that greatly reduce premiums for marketplace enrollees with incomes below 300% FPL. Researchers found that this policy increased take-up of individual marketplace coverage among eligible residents by 14 to 24 percent.<sup>72</sup>

Two states (**New York** and **Minnesota**) have implemented a Basic Health Plan option, which gives states the ability to provide more affordable coverage for low-income residents and improves continuity of care for people whose incomes fluctuate above and below Medicaid and Children's Health Insurance Program (CHIP) eligibility levels. States can provide coverage to individuals who are citizens or lawfully present noncitizens who do not qualify for Medicaid, CHIP or other minimum essential coverage if they meet the income criteria.<sup>73</sup>

**Washington** began enrollment in a Public Option hybrid model (called Cascade Care) in 2020, with coverage effective Jan. 1, 2021. Public Option plans were available in 25 of Washington's 39 counties for plan year 2022, up from 19 in plan year 2021. Because provider rates will be tied to Medicare rates, premiums are expected to decrease. However, for plan year 2022, Cascade Care Bronze plan premiums are two percent more expensive than the lowest non-standard Bronze plan on the marketplace, though many carriers report that the public option plan is their lowest priced plan in several counties. Cascade Care plans were more likely to be offered in counties where the marketplace was larger and more competitive, however premiums for the plans were lower in smaller, less competitive counties.<sup>74,75</sup>

**Nevada** and **Colorado** both passed legislation in 2021 to establish public options— by 2023 in Colorado and by 2026 in Nevada.<sup>76,77</sup>

residing immigrant pregnant women and children; 10 states covered only legally residing immigrant children; and one state, **Wyoming**, covered only legally residing immigrant pregnant women.

- ▲ Providing prenatal care to women regardless of immigration status by extending CHIP coverage to the unborn child (18 states).
- ▲ Providing health coverage for undocumented children (7 states).
- ▲ Using state funds to provide healthcare coverage/access options for undocumented immigrant adults, as **California**,<sup>78</sup> **Illinois**,<sup>79</sup> **New York City**<sup>80</sup> and **D.C.**<sup>81</sup> have done for selected populations.

**Stronger insurance premium rate review:** Rate review is the process by which state insurance regulators review health carriers' proposed insurance premiums for the coming year to ensure they are based on accurate, verifiable data and realistic projections of healthcare costs and utilization. A majority of states conduct what is termed "effective" rate review, as designated by CMS' Center for Consumer Information and Insurance Oversight. This designation reflects consideration of basic factors like medical cost trends, expected utilization of services and determinations about the reasonableness of rate increases.

However, the "effective" rate review designation does not take other important factors—like affordability, provision of high-value care or the scrutiny of provider-carrier contracts—into account. Only six states (**California, Massachusetts, Oregon, Rhode Island, Vermont and Washington**) consider at least one of these factors during their rate review process. Ensuring that insurer rates are affordable has a direct impact on consumers' out-of-pocket costs.<sup>82</sup>

**Rhode Island's** Office of the Health Insurance Commissioner established a comprehensive set of standards designed to encourage insurance companies and hospitals to reduce costs by creating more efficient systems, not by lowering the quality of care provided or reducing coverage. Strategies include requiring insurers to invest more in primary care providers and services, encouraging primary care practices to transform into Patient Centered Medical Homes and reducing costs through the adoption of payment reform strategies.<sup>83</sup>

**California** requires health plans to disclose information on recent cost containment efforts for all rate filings submitted in the individual and small group insurance markets to the Department of Managed Care.<sup>84</sup>

**Oregon's** Department of Consumer and Business Services has the authority to request data on insurance companies' cost containment and quality improvement efforts through rate filings.<sup>85</sup> Moreover, rates may not be deemed "prejudicial to the interests of the insured's policyholders."<sup>86</sup>

**Massachusetts' Department of Insurance** can require issuers to provide a detailed description of the basis upon which they pay different rates to "similarly situated" providers.<sup>87</sup> The state's Health Policy Commission can request and review issuer-provider contracts as part of its mandate to reduce healthcare cost growth in the state.<sup>88</sup>

Regulators in **Washington** state have the authority to review provider contracts—critical for learning how monopoly power might be affecting rates in local markets.<sup>89</sup>

**Vermont** requires its Green Mountain Care Board to determine whether proposed rates are affordable and promote the quality of, and access to, healthcare prior to being approved.<sup>90</sup> Vermont is also an 'active purchaser,' which helps keep premiums down on the exchange.<sup>91</sup>

In December 2020, **Delaware's** Office of Value-Based Health Care Delivery released draft affordability standards that would use rate review to enforce new targets for primary care investment, unit price growth for non-professional services and adoption of alternative payment models.<sup>92</sup> Draft rules were available for public comment until January 2021.



## MAKE OUT-OF-POCKET COSTS AFFORDABLE: POLICY AND OUTCOME FINDINGS

Even if insurance coverage was extended to the entire U.S. population, people could still face affordability problems if cost-sharing provisions or the scope of covered services leaves them underinsured (i.e., unable to afford their share of needed care after their health plan pays the bill). The Commonwealth Fund's biennial survey reveals that 21% of insured adults, ages 19-64, were underinsured in 2020.<sup>93</sup> It is well established that underinsured people mimic those without coverage by forgoing needed care.<sup>94</sup>

State policy decisions can have a profound impact on the affordability of out-of-pocket (OOP) costs, particularly in the fully insured market.<sup>95</sup> This section of the Scorecard examined the following state-level policy approaches:

- ▲ Protecting consumers from inadvertent, surprise out-of-network medical bills;
- ▲ Protecting consumers from short-term, limited-duration plans;
- ▲ Waiving or reducing cost-sharing for high-value services; and
- ▲ Deploying standard plan designs in the state-based Exchange.


The outcome score for OOP costs examines the percent of adults who could not get needed medical care due to cost.

Compared to our scan of coverage efforts, we found much less policy activity designed to ease the burden of out-of-pocket costs, with ten states taking no action at all (see Figure 4). **California** and **New York**, followed by **Connecticut**, scored highest in terms of policy actions to make out-of-pocket costs affordable, but **Hawaii** residents (followed by **Iowa**, **Rhode Island**, **Massachusetts**, **North Dakota**, and **Vermont**) reported the lowest percentages of residents who could not get needed medical care due to cost.\*


**\*Note:** As several studies have documented, difficulty affording out-of-pocket costs can manifest itself in many ways, including foregoing needed care, delaying needed care, skimping on care (such as cutting pills in half) and getting care but struggling to pay the resulting medical bills. The outcome score for this category assesses the prevalence of only one of these manifestations: forgoing needed medical care due to cost. State-level estimates from SHADAC reveal that, even in relatively high performing states like **Hawaii**, almost 1 in 10 residents report inability to get care due to cost, while in worse performing states, like **Texas**, nearly 1 in 5 adults have forgone care due to cost. The broader array of affordability burdens likely affects significantly larger shares of state residents. In some states, surveys have found that nearly 70 percent of residents have recently experienced at least one of the burdens listed above.<sup>96</sup>

**FIGURE 4: STATE SCORE COMPARISON: MAKE OUT-OF-POCKET COSTS AFFORDABLE**

### Policy Scores



### Outcome Scores



Note: NJ is not included in this chart because data on affordability burdens was not available for this state.

Appendix A lists the Extending Coverage to All Residents policy scores for all states, along with the state rank for this Scorecard component.

## A CLOSER LOOK AT THE RECOMMENDED POLICY ACTIONS:

**Protect consumers from inadvertent, surprise out-of-network medical bills:** Surprise medical bills (SMBs) include any medical bill for which a health insurer paid less than the patient expected. One form of SMB receiving a lot of attention is when patients receive a bill from an out-of-network provider that would have been difficult to avoid; for example, if they needed emergency care or received care from an out-of-network provider at an in-network hospital. These issues are particularly acute for those with private health insurance, which often features more limited provider networks and few balance billing protections, and are particularly prevalent in certain metropolitan areas, at certain institutions and for certain types of medical care.<sup>97</sup> The resulting expense can be financially devastating for individuals and families.

The federal No Surprises Act, passed in 2020, prohibits surprise medical billing in most insurance plans nationwide effective January 2022. Nevertheless, states that have not already done so should consider establishing comprehensive SMB protections to (1) shore up areas unaddressed by the Federal legislation, such as ground ambulance services which often result in surprise bills for consumers, and (2) ensure that protections will remain if the No Surprises Act is ever overturned or made less comprehensive in future legislation.

While states cannot protect consumers enrolled in self-insured plans, which are under the jurisdiction of the Federal government, they can protect consumers in fully insured plans. According to researchers at Georgetown University, state-level SMB protections must include the following components in order to be considered comprehensive:<sup>98,99</sup>

- ▲ Extend protections to both emergency department and in-network hospital settings;
- ▲ Apply laws to all types of insurance, including both HMOs and PPOs;
- ▲ Protect consumers both by shielding them from harm resulting from extra provider charges—meaning they are not responsible for the charges—and prohibiting providers from balance billing; and
- ▲ Adopt an adequate payment standard—a rule to determine how much the insurer pays the provider—or a dispute-resolution process to resolve payment disputes between providers and insurers.

In this Scorecard, 18 states received credit for comprehensive protections against surprise out-of-network bills and 15 states received credit for partial protections.

**New York** was one of the first states to enact comprehensive surprise out-of-network billing protections, requiring insurers and physicians to enter binding arbitration to settle disputed medical bills. A 2017 assessment determined that the law reduced out-of-network billing by 34% and reduced the level of in-network emergency department physician payments in the state by 9%.<sup>100</sup> A 2019 study found that provider and insurer stakeholders view the dispute resolution process as fair, with arbitration decisions roughly evenly split between the two sides.<sup>101</sup> However, another 2019 assessment found that the law's guidance to arbiters (specifically that they should consider the 80th percentile of billed charges when making their determination) may be raising costs compared to a lower benchmark.<sup>102</sup>

Typically, state-level surprise medical bill protections do not extend to large, self-insured employers, who are regulated by the federal government. A **New Jersey** law addressed this by allowing self-funded employers to opt in, extending state protections to employees in these plans. To opt-in, self-funded groups must: (1) provide an annual notice to the Department of Banking and Insurance which attests to being bound by the applicable provisions of New Jersey's law and (2) amend employee benefit plans, coverage policies and contracts in accordance with the law.<sup>103</sup>



**Protect consumers from short-term, limited-duration (STLD) health plans:** Short-term, limited-duration (STLD) health plans are not required to provide the standard ACA protections for nongroup coverage. Although they are relatively low cost, STLD plans cover little, can reject/charge higher rates for women and people with pre-existing conditions, are not well understood by consumers<sup>104</sup> and only a small percentage of the premiums collected are ultimately spent on beneficiaries' medical care.<sup>105</sup>

Though the term limit of these plans was capped at three months in 2016 under a ruling from the Obama administration, the Trump administration extended the limit to 364 days in 2018.<sup>106</sup> Some states have exercised their own authority to limit the amount of time residents can be enrolled in STLD plans and/or require STLD plan issuers to provide certain protections and benefits. For example, **California, New Jersey** and **New York** ban the sale of STLD plans altogether, while **Colorado, Connecticut, the District of Columbia, Hawaii, Rhode Island, Maine, Massachusetts, New Mexico** and **Vermont** regulate the plans so heavily that no insurers offer them in the state. Still, many states default to federal rules for STLD plans, which limit the initial plan term limit to 364 days and cap the maximum duration to 36 months.

**State mandates that waive or reduce cost-sharing for high-value services:** Failure to receive high-value care like flu vaccines, certain cancer screenings and other select services not only worsens health outcomes but can result in higher spending on medical care in the future.<sup>107</sup> Available evidence suggests that multicomponent approaches (which align financial and non-financial incentives<sup>108</sup> for both providers and patients) have the most success but, for the purposes of the Scorecard, we examine whether states have waived or reduced cost-sharing for high-value services to encourage utilization of high-value care. Of the 17 states that had passed policies to reduce financial barriers to high-value care as of Dec. 31, 2020, the most common area of action was capping costs for prescription drugs, particularly insulin.

**New Jersey** requires health plans to waive the deductible for immunizations and lead screening for children, preventive care, maternity care and second surgical opinions for people enrolled in fully insured plans.<sup>108</sup>

**Utah's** Insulin Savings Program allows any resident to purchase insulin at wholesale prices through the state and public employee plan.<sup>109</sup>

**New Hampshire** caps cost-sharing for insulin to \$30 for a 30-day supply for state-regulated commercial health insurance.<sup>110</sup>

**Standard Plan Design in the state-based Marketplace:** By standardizing cost-sharing obligations into a few basic plan designs, states can help consumers make better-informed coverage decisions and reduce financial barriers to high-value care. Standard benefit designs reduce the amount of variation consumers have to take into account when shopping for a health plan, making it easier to make a good selection. Standard plan designs are also the ideal vehicle for deploying evidence-based practices with respect to cost-sharing; for example, by utilizing copays, which are predictable and easier for consumers to understand, over co-insurance and avoiding high-deductible designs that create financial barriers to care for less-than-healthy individuals.<sup>111</sup> States can further protect consumers by requiring certain high-value services to be covered before a deductible is met and limiting copay amounts. This policy approach reduces insurers' ability to use benefit design to select favorable risk and deter enrollment by those who are sick.<sup>112</sup>

We find that seven states have policies aimed at lowering cost-sharing for specified healthcare services in the individual and/or small-group markets through state-prescribed standard plan designs: **California, Connecticut, the District of Columbia, Massachusetts, New York, Oregon, and Vermont.** In most cases, standardized plans for the individual and small-group markets are similar, if not identical. The **District of Columbia** has implemented standardized plan designs that apply only to the individual market, but will extend standardized plans to the small-group market beginning in plan year 2023.<sup>113</sup> **New York's** standardized plan design is more limited than other states' because it only provides access to prescription drugs (generic and brand name) pre-deductible.<sup>114</sup>

**Massachusetts**, whose marketplace was the first to implement plan standardization in 2010, found that standardizing plan designs made consumers more likely to accurately differentiate among plans.<sup>115</sup> Uniquely, the state requires an additional layer of standardization by defining three types of provider networks ("broadest commercial," "narrow," and "tiered").<sup>116</sup>

**Connecticut** limits cost-sharing in most plans for certain high-value services, such as primary care, and limits the number of services subject to co-insurance.<sup>117</sup>

**New Jersey's** standard plans pre-date the ACA and explicitly waive the deductible for immunizations and lead screening for children, preventive care, maternity care and second surgical opinions. The state's approach varies from other states in that it legislated benefit requirements, rather than developing standardized cost-sharing requirements based on value-based insurance design principles.<sup>118</sup>

**Oregon's** standardized benefit plans include the following pre-deductible services with low to moderate copay amounts: non-preventive primary care, specialty care, laboratory and diagnostic testing, mental health and substance use disorder treatment, urgent care and generic prescription drugs.<sup>119</sup> Additionally, Oregon is the only state with benefit designs that feature higher cost-sharing for services that are considered overused within its educator and public employee plans.<sup>120,121</sup>

## CONCLUSION

The Healthcare Value Hub's Healthcare Affordability State Policy Scorecard uses a unique dataset that compiles state-level activity with respect to both policy and outcomes measures across four healthcare affordability domains. The exercise shows promising movement across states in terms of both policies and outcomes, but also significant areas of inaction where states are falling short. The Scorecard reveals the robust policy toolset that state policymakers have to address healthcare affordability by tackling the underlying drivers of affordability problems—most notably, excess prices—and ensuring that all residents can access coverage options with affordable premiums and cost-sharing provisions. By providing language, a toolset and state-specific case studies, this report helps policymakers and others tie the recommended evidence-based policy actions to state residents' top priority—healthcare affordability. Moreover, the Scorecards and related products empower healthcare advocates and consumers to hold their elected officials accountable for addressing the burden of healthcare affordability.



## NOTES

1. Healthcare Value Hub, [What Do Consumers Say?](#) (accessed on Dec. 8, 2021).
2. Healthcare Value Hub, [Consumer Healthcare Experience State Survey](#). See also: Robert Wood Johnson Foundation, [Healthcare Affordability: Majority of Adults Support Significant Changes to the Health System](#), (accessed on Dec. 2, 2021).
3. Available by state on Healthcare Value Hub, [Healthcare Affordability State Policy Scorecard](#), Washington, D.C. (2021).
4. The Build Back Better Act, introduced in the U.S. House of Representatives in September 2021, includes several healthcare affordability-related provisions that—if passed—would be implemented on a national scale. The legislation had passed the House and was under consideration by the Senate at the time of this publication. H.R. 5376, Build Back Better Act, House of Representatives, 2021-2022 Regular Session (U.S. Congress, 2021). Accessed at <https://www.congress.gov/bill/117th-congress/house-bill/5376?q=%7B%22search%22%3A%5B%22build+back+better%22%2C%22build%22%2C%22back%22%2C%22better%22%5D%7D&s=5&r=1>
5. The analysis used to determine these rankings was specially produced for Altarum by Johns Hopkins University and, therefore, differs from the widely used Whaley-RAND study: [https://www.rand.org/pubs/research\\_briefs/RBA1144-1.html](https://www.rand.org/pubs/research_briefs/RBA1144-1.html). For more information, see: Allen, Alexandra, Amanda Hunt and Lynn Quincy, [Healthcare Affordability State Policy Scorecard Methodology](#), Healthcare Value Hub (November 2021).
6. Cooper, Zack, et al., [The Price Ain't Right? Hospital Prices and Health Spending on the Privately Insured](#), The National Bureau of Economic Research (May 2018).
7. Shrank, William H., Teresa L. Rogstad and Natasha Parekh, "Waste in the U.S. Health Care System Estimated Costs and Potential for Savings," *JAMA* (Oct. 7, 2019).
8. Health Care Cost Institute, [Healthy Marketplace Index](#) (accessed on Dec. 10, 2021).
9. See Scorecard methodology report for additional information: [https://www.healthcarevaluehub.org/application/files/3416/3587/7032/2021\\_Healthcare\\_Affordability\\_Scorecard\\_-\\_Methodology\\_1.pdf](https://www.healthcarevaluehub.org/application/files/3416/3587/7032/2021_Healthcare_Affordability_Scorecard_-_Methodology_1.pdf)
10. Johnson, Annaliese, and Lynn Quincy, [Hospital Rate Setting: Successful in Maryland but Challenging to Replicate](#), Healthcare Value Hub, Washington, D.C. (May 2020).
11. Healthcare Value Hub, [All-Payer Claims Databases: Unlocking Data to Improve Healthcare Value](#), Washington, D.C. (September 2015).
12. Georgia, Hawaii, Indiana, New Mexico and West Virginia received partial credit for APCDs that were underway.
13. Oregon Health Authority, [Oregon All-Payer All Claims Database \(APAC\) Use Case Document](#), Salem, O.R. (August 2018).
14. S.B. 482, Office of Health Strategy and Coordination; state all-payer claims database; establishment of an advisory committee; provide, Senate, 2020 Regular Session (Georgia 2020). Accessed at <https://www.legis.ga.gov/legislation/58021>
15. Montague, Alex, [Spotlight on State: Georgia, The Source on Healthcare Price and Competition](#) (March 8, 2021).
16. Georgians for a Healthy Future, [Legislative Update: Steep Budget Cuts and Significant Health Bills Close 2020 Session](#), (Accessed on Dec. 8, 2021).
17. Healthcare Value Hub, [Oregon 2021 Healthcare Affordability Policy Checklist](#), Washington, D.C. (October 2021). ; Healthcare Value Hub, [Connecticut 2021 Healthcare Affordability Policy Checklist](#), Washington, D.C. (October 2021).
18. Massachusetts Health Policy Commission, [2021 Annual Health Care Cost Trends Report](#), Boston, M.A. (September 2021).
19. Odom Walker, Kara, "Can a Small State Improve Both Health Care Costs and Health Outcomes? Lessons From Delaware," *Health Affairs Blog* (June 6, 2019).
20. Connecticut Office of Health Strategy, [Cost Growth and Quality Benchmarks, and Primary Care Target](#) (accessed on Dec. 8, 2021).

21. Krishnan, Sunita, *Health System Oversight by States: An Environmental Scan*, Healthcare Value Hub, Washington, D.C. (November 2017).
22. Maryland Health Services Cost Review Commission, About Us (accessed on Dec. 8, 2021).
23. Colorado Lieutenant Governor, Office of Saving People Money on Health Care, <https://ltgovernor.colorado.gov/programs/office-of-saving-people-money-on-health-care> (accessed on Dec. 8, 2021).
24. Krishnan, Sunita (May 2018).
25. Cooper, et al. (May 2018).
26. Quincy, Lynn and Amanda Hunt, *Revealing the Truth about Healthcare Price Transparency*, Healthcare Value Hub, Washington, D.C. (June 2018).
27. Human Services Research Institute, CompareMaine Healthcare Transparency Website, <https://www.hsri.org/project/comparemaine-healthcare-transparency-website> (accessed on Dec. 8, 2021).
28. Moffit, Robert E., et al., “The Next Chapter in Transparency: Maryland’s Wear the Cost,” *Health Affairs Blog* (Oct. 19, 2017).
29. Utah Office of the State Auditor, *Utah Health Cost Compare* (accessed on Dec. 8, 2021).
30. H.B. 178, Transparency Website Amendments, House 2019 General Session (Utah 2019). Accessed at <https://le.utah.gov/~2019/bills/static/HB0178.html>
31. Hunt, Amanda, *Six Categories of Healthcare Waste: Which Reign Supreme?*, Healthcare Value Hub blog (October 2019).
32. Multi-stakeholder strategies, with roles for policy, providers and patients, are very promising. For more information, see Beaudin-Seiler, Beth, Lynn Quincy and Rebecca Cooper, *Reducing Low-Value Care: Saving Money and Improving Health*, Healthcare Value Hub, Washington, D.C. (November 2018).
33. Beaudin-Seiler, Beth, et al., “Reducing Low-Value Care,” *Health Affairs Blog* (Sept. 20, 2016). /
34. A lack of standardized nomenclature and overlapping definitions of medical errors has hindered data analysis, synthesis and evaluation. See Rodziewicz, Thomas L., Benjamin Houseman and John E. Hipskind, “Medical Error Reduction and Prevention,” *StatPearls* (January 2021). To help bridge this gap, a taxonomy of medical harm is available from the Healthcare Value Hub: McGiffert, Lisa, *Medical Harm: A Taxonomy*, Healthcare Value Hub, Washington, D.C. (November 2015).
35. Some harms cannot be avoided in clinical practice. For example, some adverse drug reactions which occur in the absence of any error in the prescription process and without the possibility of detection are less likely to be preventable. See Panagioti, Maria, et al., “Prevalence, Severity, and Nature of Preventable Patient Harm Across Medical Care Settings: Systematic Review and Meta-Analysis,” *BMJ* (July 2019).
36. Ibid. See also, Healthcare Value Hub, *Cost & Quality Problems: Medical Harm* (accessed on Dec. 8, 2021).
37. In their 1999 report, *To Err is Human*, the Institute of Medicine called for public reporting in state systems and emphasized transparency as one of 10 principles that should guide the redesign of the healthcare system. The Deficit Reduction Act of 2005 modified payment for acute-care hospitalizations of Medicare fee-for-service beneficiaries if a complicating condition occurred during the hospitalization that could have reasonably been prevented. As a result, hospitals must track and analyze instances of patient harm as a condition of participation in the Medicare program. Hospitals can demonstrate their compliance through a survey by a state survey agency or accreditation under an approved Medicare accreditation program. See Levinson, Daniel R., *Hospital Incident Reporting Systems Do Not Capture Most Patient Harm*, Department of Health and Human Services, Office of Inspector General (Jan. 5, 2012).
38. Bernazzani, Sophia, *Tallying the High Cost of Preventable Harm*, Costs of Care (accessed Dec. 10, 2021).
39. Centers for Disease Control and Prevention, *Current Healthcare-Associated Infections (HAI) Progress Report*, Centers for Disease Control and Prevention (October 2021).
40. Levinson (January 2012).

41. Centers for Disease Control and Prevention (October 2021).
42. Fleming, Katherine, E., et al., “[Prevalence of Inappropriate Antibiotic Prescriptions Among U.S. Ambulatory Care Visits, 2010-2011](#),” *JAMA*, Vol. 315, No. 17 (May 2016).
43. Association of State and Territorial Health Officials, [Antimicrobial Stewardship](#) (accessed on Dec. 10, 2021).
44. Centers for Disease Control and Prevention, [Antibiotic Use in the United States, 2021 Update: Progress and Opportunities](#), Atlanta, G.A. (Nov. 1, 2021).
45. Centers for Disease Control and Prevention, [Hospital Antibiotic Stewardship](#) (accessed on Dec. 8, 2021).
46. While not the only source for identifying low-value care, the American Board of Internal Medicine Foundation’s Choosing Wisely initiative is one of the most widely recognized. The campaign aggregates recommendations from industry experts on how to reduce low-value care and distributes that information to clinicians and patients. For more information, see: <https://www.choosingwisely.org/>
47. Reid, Rachel O., Brendan Rabideau, and Neeraj Sood, “[Low-value Health Care Services in a Commercially Insured Population](#),” *JAMA Internal Medicine*, Vol. 176, No. 10 (October 2016).
48. Buxbaum, Jason D., John N. Mafi and A. Mark Fendrick, “[Tackling Low-Value Care: A New ‘Top Five’ for Purchaser Action](#),” *Health Affairs* (November 2017).
49. Beaudin-Seiler (November 2018).
50. Claims and other administrative data typically used to identify low-value care may lack the variables needed to assess the clinical nuance.
51. Schwartz, Aaron L., et al., “[Measuring Low-Value Care in Medicare](#),” *JAMA Internal Medicine* (July 2014).
52. LaPointe, Jacqueline, “Low-Cost, Low-Value Resource Use Drives \$586M in Wasteful Spending,” *Revcycle Intelligence* (Oct. 4, 2017).
53. Virginia Center for Health Innovation, [Virginia Receives a \\$2.2M Grant to Tackle the Overuse of Unnecessary Health Care](#) (accessed on Dec. 8, 2021).
54. Center for Improving Value in Health Care, [Low Value Care in Colorado](#), Denver, C.O. (March 2020).
55. Keisler-Starkey, Katherine and Lisa N. Bunch, [Health Insurance Coverage in the United States: 2020](#), United States Census Bureau, Washington, D.C. (September 2021).
56. Garfield, Rachel, Kendal Orgera and Anthony Damico, [The Uninsured and the ACA: A Primer—Key Facts about Health Insurance and the Uninsured Amidst Changes to the Affordable Care Act](#), Kaiser Family Foundation Washington, D.C. (January 2019).
57. Ibid.
58. Ungar, Laura, “[The Deep Divide: State Borders Create Medicaid Haves and Have-Nots](#),” *Kaiser Health News* (October 2019).
59. Garfield, Rachel, Kendal Orgera and Anthony Damico, [The Coverage Gap: Uninsured Poor Adults in States that Do Not Expand Medicaid](#), Kaiser Family Foundation Washington, D.C. (March 21, 2019). See also: Gideon Lukens, [Medicaid Coverage Gap Affects Even Larger Group Over Time Than Estimates Indicate](#), Center on Budget and Policy Priorities, Washington, D.C. (Sept. 3, 2021).
60. Guth, Madeline and Meghana Ammula, [Building on the Evidence Base: Studies on the Effects of Medicaid Expansion, February 2020 to March 2021](#), Kaiser Family Foundation, San Francisco, C.A. (May 6, 2021).
61. Healthcare.gov, [Federal Poverty Level](#) (accessed on Dec. 7, 2021).
62. Garfield (2019). See also: Gideon Lukens, [Medicaid Coverage Gap Affects Even Larger Group Over Time Than Estimates Indicate](#), Center on Budget and Policy Priorities, Washington, D.C. (Sept. 3, 2021).

63. Guth, Madeline, Rachel Garfield and Robin Rudowitz, *The Effects of Medicaid Expansion under the ACA: Studies from January 2014 to January 2020*, Kaiser Family Foundation, Washington, D.C. (March 17, 2020).
64. Healthcare Value Hub, *Missouri 2021 Healthcare Affordability Policy Checklist*, Washington, D.C. (October 2021).
65. Healthcare Value Hub, *Oklahoma 2021 Healthcare Affordability Policy Checklist*, Washington, D.C. (October 2021).
66. Healthcare Value Hub, *South Dakota 2021 Healthcare Affordability Policy Checklist*, Washington, D.C. (October 2021).
67. Justin Giovannelli, *A Permanent Boost to Federal Premium Assistance Could Change State Approaches to ACA 1332 Waivers*, The Commonwealth Fund, New York, N.Y. (May 3, 2021).
68. *Health Coverage of Immigrants*, Kaiser Family Foundation, San Francisco, C.A. (July 15, 2021).
69. Ibid.
70. Ibid.
71. *Delaware Receives Federal Approval to Establish Reinsurance Program for 2020*, Delaware.gov (accessed on Dec. 13, 2021).
72. Finkelstein, Amy, Nathaniel Hendren and Mark Shepard, "Subsidizing Health Insurance for Low-Income Adults: Evidence from Massachusetts," *American Economic Review*, Vol. 109, No. 4 (April 2019).
73. Federal funding of these designs is imperiled. For more information, see King, Robert, "Health Program Proposal May Cause New York, Minnesota to Lose Millions," *Modern Healthcare* (March 2019).
74. Sen, Aditi P., et al., "Participation, Pricing, and Enrollment in a Health Insurance "Public Option": Evidence from Washington State's Cascade Care Program," *The Milbank Quarterly* (Nov. 23, 2021).
75. O'Brien, Madeline, *Encouraging Signs for the Public Option in Washington State: Improved Availability and Affordability of Plans in 2022*, Center on Health Insurance Reforms (Dec. 3, 2021).
76. Colorado Department of Regulatory Agencies, *Colorado Option* (accessed on Dec. 8, 2021).
77. Messerly, Megan and Sean Golonka, "Sisolak Signs Bill Making Nevada the Second State to Adopt a Public Health Insurance Option," *The Nevada Independent* (June 9, 2021).
78. Healthcare Value Hub, *California 2021 Healthcare Affordability Policy Checklist*, Washington, D.C. (October 2021).
79. Healthcare Value Hub, *Illinois 2021 Healthcare Affordability Policy Checklist*, Washington, D.C. (October 2021).
80. Healthcare Value Hub, *New York 2021 Healthcare Affordability Policy Checklist*, Washington, D.C. (October 2021).
81. Healthcare Value Hub, *District of Columbia 2021 Healthcare Affordability Policy Checklist*, Washington, D.C. (October 2021).
82. For more information, see Healthcare Value Hub, *Improving Value: Insurance Rate Review*.
83. Office of the Health Insurance Commissioner, State of Rhode Island, *Reform and Policy—Affordability Standards* (accessed on Dec. 8, 2021).
84. California Insurance Code 10181.3(c)(3). Accessed at [https://leginfo.ca.gov/faces/codes\\_displayText.xhtml?lawCode=INS&division=2.&title=&part=2.&chapter=1.&article=4.5](https://leginfo.ca.gov/faces/codes_displayText.xhtml?lawCode=INS&division=2.&title=&part=2.&chapter=1.&article=4.5).
85. H.B. 2009, Establishing Oregon Health Policy Board, House, 2009 Regular Session (Oregon 2009). Accessed at <https://olis.oregonlegislature.gov/liz/2009R1/Downloads/MeasureDocument/HB2009/Enrolled>
86. Oregon Insurance Policies Generally; Property and Casualty Policies, 742.005, accessed at [https://www.oregonlegislature.gov/bills\\_laws/ors/ors742.html](https://www.oregonlegislature.gov/bills_laws/ors/ors742.html)
87. Massachusetts Division of Insurance, *Health Maintenance Organizations* (accessed on Dec. 7, 2021); Massachusetts Division of Insurance, *Small Group Health Insurance* (accessed on Dec. 7, 2021).
88. Commonwealth of Massachusetts, Chapter 6D, Section 8, Public hearings; Witnesses; Annual Report, Accessed at <https://malegislature.gov/Laws/GeneralLaws/PartI/TitleII/Chapter6D/Section8>

89. Washington Statutes (WAC 284-170-421), Provider Contracts—Standards—Hold Harmless Provisions. Accessed at <https://app.leg.wa.gov/wac/default.aspx?cite=284-170-421>
90. Vermont Green Mountain Care Board, *Health Insurance Premium Rate Review*, Montpelier, V.T. (July 2020).
91. Krinn, Kelly, Pinar Karaca-Mandic and Lynn A. Blewett, “State-Based Marketplaces Using ‘Clearinghouse’ Plan Management Models Are Associated With Lower Premiums,” *Health Affairs*, Vol. 34, No. 1 (January 2015).
92. Delaware Department of Insurance, Office of Value-Based Health Care Delivery, *Delaware Health Care Affordability Standards: An Integrated Approach to Improve Access, Quality and Value* (Dec. 18, 2020).
93. As defined by the Commonwealth Fund, people who are “underinsured” have health plan deductibles and out-of-pocket medical expenses that are high relative to their income. For more information, see Collins, Sara R., Munira Z. Gunja and Gabriella N. Aboulafia, *U.S. Health Insurance Coverage in 2020: A Looming Crisis in Affordability*, The Commonwealth Fund, New York, N.Y. (Aug. 19, 2020).
94. Ibid.
95. Individual, or nongroup and small-group coverage are typically regulated at the state level, whereas the coverage offered by larger employers typically takes for the form of self-insured coverage and is regulated (lightly) by the U.S. Department of Labor. Unfortunately, much of the increase in underinsurance is among those with employer coverage. Ibid.
96. Healthcare Value Hub, *Georgia Consumer Healthcare Experience State Survey*, Washington, D.C. (2021).
97. Sanger-Katz, Margot, and Reed Abelson, “Surprise! Insurance Paid the E.R. But Not the Doctor,” *The New York Times* (November 2016).
98. Primary source augmented by additional Healthcare Value Hub review was Kona, Maanasa, *State Balance-Billing Protections*, The Commonwealth Fund, New York, N.Y. (Feb. 5, 2021).
99. To search for bills and statutes in all 50 states as they related to surprise billing regulations, see *The Source on Healthcare Price & Competition, The Database of State Laws Impacting Healthcare Cost & Quality*.
100. Cooper, Zack, Fiona Scott Morton and Nathan Shekita, *Surprise! Out-of-Network Billing for Emergency Care in the United States*, National Bureau of Economic Research (Revised January 2019).
101. Corlette, Sabrina, and Olivia Hoppe, *New York’s 2014 Law to Protect Consumers from Surprise Out-of-Network Bills Mostly Working as Intended: Results of a Case Study*, Georgetown University Health Policy Institute, Center on Health Insurance Reforms (May 2019).
102. Adler, Loren, *Experience with New York’s Arbitration Process for Surprise Out-of-Network Bills*, USC-Brookings Schaeffer on Health Policy (October 2019).
103. A.2039, Out-of-network Consumer Protection, Transparency, Cost Containment and Accountability Act, Assembly, 2018-2019 Regular Session (New Jersey 2018). Accessed at <https://legiscan.com/NJ/bill/A2039/2018>
104. Gantz, Sarah, “A Philly Woman’s Broken Back and \$36,000 Bill Show How Some Health Insurance Brokers Trick Consumers into Skimpy Plans,” *The Philadelphia Inquirer* (Nov. 14, 2019).
105. Pollitz, Karen, et al., *Understanding Short-Term Limited Duration Health Insurance*, Kaiser Family Foundation, San Francisco, C.A. (April 23, 2018).
106. Pear, Robert, “‘Short Term’ Health Insurance? Up to 3 Years Under New Trump Policy,” *The New York Times* (Aug. 1, 2018).
107. Cooper, Rebecca, and Lynn Quincy, *High-Value Care: Strategies to Address Underuse*, Healthcare Value Hub, Washington, D.C. (November 2018).
108. Hunt, Amanda, *Non-Financial Provider Incentives: Looking Beyond Provider Payment Reform*, Healthcare Value Hub, Washington, D.C. (February 2018).
109. New Jersey Individual Health Coverage Program Board, *Standard Policy Form for the Individual Health Benefits Plan* (accessed on Dec. 8, 2021).



110. Roe, Ginna, [Utah Health Insurer to Launch State's First-Ever Insulin Savings Program](#), KUTV (May 14, 2020).
111. Schaffer, Regina, ["New Hampshire Law Caps Monthly Insulin Copay at \\$30,"](#) Healio (July 17, 2020).
112. Quincy, Lynn, [What's Behind the Door: Consumer Difficulties Selecting Health Plans](#), Consumers Union (Jan 10, 2012).
113. Corlette, Sabrina, et al., [Missed Opportunities: State-Based Marketplaces Fail to Meet Stated Policy Goals of Standardized Benefit Designs](#), Urban Institute (July 2016).
114. DC Health Link, [D.C. Health Benefit Exchange Authority Takes Action to Achieve Social Justice and Equity in Health Insurance Coverage](#) (accessed on Dec. 8, 2021).
115. Lueck, Sarah, [Designing Benefit Standards for a Health Insurance Exchange](#), Center on Budget and Policy Priorities (May 21, 2009).
116. Corlette, Sabrina, et al. (July 2016).
117. [Striving for Meaningful Choice: Non-Group Health Plans on the Massachusetts Health Connector Product Shelf](#), Massachusetts Health Connector, Worcester, M.A. (January 2019).
118. Corlette, Sabrina, et al. (July 2016).
119. Ahn, Sandy and Sabrina Corlette, [State Efforts to Lower Cost-Sharing Barriers to Health Care for the Privately Insured](#), Urban Institute, Washington, D.C. (June 2017).
120. Ibid.
121. National Conference of State Legislators, [Value-Based Insurance Design](#) (Accessed Dec. 15, 2021).
122. Delbanco, Suzanne F., et al., [Benefit Designs: How They Work](#), Urban Institute, Washington, D.C. (April 2016).



#### ABOUT THE HUB

With support from Arnold Ventures and the Robert Wood Johnson Foundation, the Healthcare Value Hub provides free, timely information about the policies and practices that address high healthcare costs and poor quality, bringing better value to consumers. The Hub is part of Altarum, a nonprofit organization with the mission of creating a better, more sustainable future for all Americans by applying research-based and field-tested solutions that transform our systems of health and healthcare.

**Contact the Hub:** 2000 M Street, NW, Suite 400, Washington, DC 20036  
(202) 828-5100 | [www.HealthcareValueHub.org](http://www.HealthcareValueHub.org) | [@HealthValueHub](https://twitter.com/HealthValueHub)

# APPENDIX A: HOW STATES SCORED ON POLICIES TO ADDRESS HEALTHCARE AFFORDABILITY

	CURB EXCESS PRICES		REDUCE LOW-VALUE CARE		EXTEND COVERAGE TO ALL RESIDENTS		MAKE OUT-OF-POCKET COSTS AFFORDABLE		TOTAL SCORE (OUT OF 80)	STATE RANK
State	Policy Score	Outcome Score	Policy Score	Outcome Score	Policy Score	Outcome Score	Policy Score	Outcome Score		
AL	0	6.4	2.4	3	1	5.6	0	0.7	19.1	45
AK	0	0.1	0.7	8	6	4	0	5	23.8	41
AZ	0	5.1	0.6	4	3	4.6	2	4.6	23.9	40
AR	3	7.2	0.8	5	5	6	0	3	30	31
CA	3	1.7	1.8	5	10	6.9	10	6.5	44.9	12
CO	7	3.4	9.6	6	7.5	6.8	8.6	6.3	55.2	5
CT	6	2.7	1.8	5	4.5	8.1	9.6	8.4	46.1	11
DE	9	5	1	5	7.5	7.7	6	7.7	48.9	10
DC	0	6.1	2	5	6	9.7	5.6	7.9	42.3	16
FL	4	2.3	1.9	4	1.6	3.4	4	2.6	23.8	41
GA	1.5	3.4	0.7	4	1	3.2	4	1	18.8	47
HI	1.5	N/A	0.3	7.0	4.5	9.2	1.6	10	N/A	N/A
ID	0	4.1	0.6	8	3	4.9	0	4	24.6	37
IL	0	5.2	0.7	5	6.0	7.1	7.6	5.2	36.8	20
IN	1.5	0.7	2.8	5	3	6.3	2.6	5.8	27.7	33
IA	0	7.3	0.6	8	3.6	8.7	2.6	9.7	40.5	17
KS	3	6.7	0.3	4	1	6	0	5.3	26.3	36
KY	0	6.5	1.8	4	3.6	7.8	0.6	6.3	30.6	29
LA	0	8.3	0.5	5	4.1	6.2	3	3.8	30.9	27
ME	4.3	2.2	8.2	10	7.5	6.8	8.6	6.1	53.7	9
MD	6.5	10	2.9	5	7.5	8.1	7.6	7.5	55.1	6
MA	10	3.8	10	5	9.3	10	7.6	9.6	65.3	1
MI	3	6.3	0.7	5	3.5	8.2	4.6	6.7	38	18
MN	3	2.7	9.6	8	8	8.8	5.6	8.3	54	8
MS	0	7.2	1.6	3	1	3.5	2	1.5	19.8	44
MO	3	5.9	0.7	6	1.5	5.5	2	4.3	28.9	32
MT	0	1.3	0.2	7	6.6	6.6	0.6	8	30.3	30
NE	0	5.1	0.7	5	5	6.6	2.6	5.9	30.9	27
NV	0	5.6	1.3	3	3.6	4.5	2.6	3.5	24.1	38
NH	4.3	3	1.9	9	3	7.9	7.6	7	43.7	14
NJ	0	2.9	1.9	3.0	8	6.8	9	N/A	N/A	N/A
NM	1.5	4.1	1.1	7	4.5	5.5	5.6	4.7	34	24
NY	3.3	0	0.8	6	8.3	8.6	10	6.9	43.9	13
NC	0	3.5	1.9	6	2.5	4.6	2	2.7	23.2	43
ND	0	6.1	0	6	6	7.5	0.6	9	35.2	23
OH	0.3	5.6	1.7	5	4.5	7.7	5	6.3	36.1	20
OK	3	5.9	0.6	4	0.5	2.7	0	2.4	19.1	45
OR	7	1.9	9.4	8	8.4	7.3	8.6	5	55.6	4
PA	1	5.5	2.8	3	4.5	8.2	2	8.3	35.3	22
RI	7	9.5	9	2	8.1	9.3	3.6	9.6	58.1	2
SC	3	N/A	1.9	3	2.5	4.9	0	3.7	N/A	N/A
SD	0	5.5	1.3	9	1.5	5.3	0	8.5	31.1	26
TN	0	8.7	2.8	4	1.5	5.4	0.6	3.7	26.7	35
TX	3	4.6	1.6	3	1.1	0	4.6	0	17.9	48
UT	4	6.2	0.9	5	3.6	5.6	3	4.2	32.5	25
VT	9	3.3	1.8	9	8.5	9	7.6	8.9	57.1	3
VA	3	3.6	9.9	5	4.5	6.8	4	6.4	43.2	15
WA	7	1.8	8.4	8	9.3	7.7	5	6.9	54.1	7
WV	1.5	1.2	1.7	4	4.5	7.6	2	5.1	27.6	34
WI	3	2.8	1.8	7	7	8.2	0	7.7	37.5	19
WY	3	3.8	0.3	7	0.9	4	0	5	24	39

For complete methodology, detailed state scorecards and more, see: [www.HealthcareValueHub.org/Affordability-Scorecard](http://www.HealthcareValueHub.org/Affordability-Scorecard)